Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Eyenovia (NASDAQ:EYEN – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.
Risk & Volatility
Mirum Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
Valuation and Earnings
This table compares Mirum Pharmaceuticals and Eyenovia”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $307.03 million | 7.34 | -$163.41 million | ($2.02) | -23.24 |
| Eyenovia | $31,832.00 | 219.13 | -$27.26 million | ($0.73) | -0.09 |
Profitability
This table compares Mirum Pharmaceuticals and Eyenovia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -31.69% | -41.22% | -14.81% |
| Eyenovia | -114,639.41% | -1,108.24% | -139.36% |
Insider & Institutional Ownership
25.8% of Eyenovia shares are held by institutional investors. 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Eyenovia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Mirum Pharmaceuticals and Eyenovia, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 0 | 0 | 10 | 1 | 3.09 |
| Eyenovia | 0 | 4 | 0 | 0 | 2.00 |
Mirum Pharmaceuticals currently has a consensus target price of $57.10, suggesting a potential upside of 21.62%. Eyenovia has a consensus target price of $2.00, suggesting a potential upside of 3,094.89%. Given Eyenovia’s higher possible upside, analysts clearly believe Eyenovia is more favorable than Mirum Pharmaceuticals.
Summary
Mirum Pharmaceuticals beats Eyenovia on 8 of the 15 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
About Eyenovia
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
